Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT)

References

• Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003; 13(Suppl 3)S69–75
   PubMed Web of Science ®Google Scholar
• Behnke K, Sogaard J, Martin S, Bäuml J, Ravindran A, Agren H, Vester-Blokland E. Mirtazapine orgally disintegrating tablet versus sertraline: A prospective onset of action study. J Clin Psychopharmacol 2003; 23: 358–364
   PubMed Web of Science ®Google Scholar
• Roose, S. Multi-site, open-label, observational study of the effectiveness and safety of mirtazapine orally disintegrating tablets in depressed patients who were at least 50 years of age. Presented at the 15th Annual Meeting of the American Association of Geriatric Psychiatry; 24–27, February, 2002, Orlando, Florida
   Google Scholar
• Delini-Stula A, Bischof R. The results of the Swiss observational study of the new, fast-dissolving mirtazapine formulation in depressed patients. J Psychiatr Clin Pract 2007; 10(2)124–30
   Google Scholar
• De Haan L, Van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389–90
   PubMedGoogle Scholar
• Stip E, Anselmo K, Wolfe M, Lessard C, Landry P. Long-term treatment with atypical antipsychotics and risk of weight gain. Drug Saf 2006; 29: 550–2
   PubMedGoogle Scholar
• Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11)37–41
   PubMed Web of Science ®Google Scholar
• Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997; 96(Suppl 391)31–7
   PubMedGoogle Scholar
• Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. J AIDS 2004; 37(4)1470–6
   PubMed Web of Science ®Google Scholar
• Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19(11)1111–7
   PubMed Web of Science ®Google Scholar
• Lee R, Taira DA. Adherence to oral hypoglycemic agents in Hawaii. Prev Chronic Dis 2005; 2(2)A09
   PubMedGoogle Scholar
• Corda RS, Burke HB, Horowitz HW. Adherence to prescription medications among medical professionals. South Med J 2000; 93(6)585–9
   PubMedGoogle Scholar
• Van Oers HJJ, Simmons JH, Van Willigenburg APP. Global preference survey shows that patients prefer fast dissolving tablets and compliance improves with this novel formulation. Int J Neuropsychopharmacol 2006; 9(Suppl 1)S83
   PubMedGoogle Scholar
• Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996; 73: 37–42
   PubMed Web of Science ®Google Scholar
• Den Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10(Suppl 4)19–23
   Google Scholar
• CIMA Labs INC. Internal report. CIMA Labs Inc, Brooklyn Park, Minnesota, 2002.
   Google Scholar
• Delini-Stula, A, Bischof, R, Desax, A. Antidepressant efficacy and patient acceptance of a new formulation of Mirtazapine (Remeron SolTab®) in depressed patients in practice. Eur J Neurpsychopharmacol, (Abstr ECNP Congress, 9–13 October, Stockholm, Sweden, 2004.
   Google Scholar
• Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003; 64(8)921–6
   PubMed Web of Science ®Google Scholar
• Zhang JS, Liu TQ, Hao W, Xie GR, Su LY, Yue WH. Control study of mirtazapine and fluoxetine in therapy of depression. Zhongguo Linchuang Kangfu 2003; 7: 4102–4
   Google Scholar
• Frijlink HW. Benefits of different drug formulations in psychopharmacology. Eur Neuropsychopharmacol 2003; 13(Suppl 3)S77–84
   Google Scholar
• Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharm Sci Technolo Today 2000; 3(4)138–145
   PubMedGoogle Scholar
• Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. J Am Med Assoc 2002; 288(22)2880–3
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. J Am Med Assoc 2002; 288(22)2868–79
   PubMed Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150(9)1881–4
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24(2)302–16
   PubMedGoogle Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8)1296–310
   PubMed Web of Science ®Google Scholar
• Balon R, Arfken CL, Mufti R. Patients' preferences about medication dosing regimens. Psychiatr Serv 1998; 49(8)1095
   PubMedGoogle Scholar
• Viale G. An economic analysis of physician prescribing of selective serotonin reuptake inhibitors. Hosp Pharm 1998; 33: 847–50
   Google Scholar
• Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 2006; 90(2–3)217–21
   PubMedGoogle Scholar